April 3, 2013
Canada-based Valeant Pharmaceuticals International is to acquire topical aesthetic and therapeutic skincare company Obagi Medical Products for $19.75 per share in cash, or $360m, which represents a 28% premium on Obagi’s share price. In 2012, Obagi reported sales of $120m.